Patents by Inventor Sarah Fernandes

Sarah Fernandes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Particle delivery systems
    Patent number: 11976277
    Abstract: Provided herein are delivery particle systems (XDP) useful for the delivery of payloads of any type. In some embodiments, a XDP particle system with tropism for target cells of interest is used to deliver CRISPR/Cas polypeptides (e.g., CasX proteins) and guide nucleic acids (gNA), for the modification of nucleic acids in target cells. Also provided are methods of making and using such XDP to modify the nucleic acids in such cells.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: May 7, 2024
    Assignee: Scribe Therapeutics Inc.
    Inventors: Jason Fernandes, Sean Higgins, Isabel Colin, Hannah Spinner, Matthew Gardner, Trent Gomberg, Gayathri Vijayakumar, Sarah Denny, Brett T. Staahl, Maroof Adil, Benjamin Oakes, Angus Sidore, Suraj Makhija
  • COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9
    Publication number: 20240124537
    Abstract: Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin/kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.
    Type: Application
    Filed: November 21, 2023
    Publication date: April 18, 2024
    Inventors: Jason FERNANDES, Sean HIGGINS, Sarah DENNY, Ross WHITE, Emeric Jean Marius CHARLES, Addison WRIGHT, Benjamin DEMAREE, Manuel MOHR, Wenyuan ZHOU, Benjamin OAKES
  • COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9
    Publication number: 20240123089
    Abstract: Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.
    Type: Application
    Filed: November 21, 2023
    Publication date: April 18, 2024
    Inventors: Jason FERNANDES, Sean HIGGINS, Sarah DENNY, Ross WHITE, Emeric Jean Marius CHARLES, Addison WRIGHT, Benjamin DEMAREE, Manuel MOHR, Wenyuan ZHOU, Benjamin OAKES
  • METHODS OF TREATMENT WITH MYOSIN MODULATOR
    Publication number: 20230158027
    Abstract: Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments. Due to observations unfolding in clinical trials with mavacamten and with mavacamten and other myosin inhibitors in the pre-clinical setting, new insights into how myosin inhibitors can be used beneficially to impact the disease state of HCM and other diseases are provided herein.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 25, 2023
    Inventors: Timothy Carlson, Carlos L. Del Rio, Jay M. Edelberg, Sarah Fernandes, Marcus Patrick Henze, Yanfei Ma, Robert McDowell, Matthew Edwards Mealiffe, Amy Sehnert, Marc J. Semigran, Kathy L. Lampl, David Zhang, Milind Y. Desai, Steve E. Nissen, Liang Fang, Joseph Lambing, Wanying Li, Danielle L. Aubele, Brian Edmund Kane, Louis Charles Sehl